Latest Insider Transactions at Collegium Pharmaceutical, Inc (COLL)
This section provides a real-time view of insider transactions for Collegium Pharmaceutical, Inc (COLL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of COLLEGIUM PHARMACEUTICAL, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of COLLEGIUM PHARMACEUTICAL, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2022
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
1,989
-0.61%
|
$43,758
$22.02 P/Share
|
|
Nov 18
2022
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,989
+0.61%
|
$29,835
$15.9 P/Share
|
|
Oct 04
2022
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,350
-4.6%
|
$73,950
$17.35 P/Share
|
|
Sep 15
2022
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
38,589
-26.06%
|
$694,602
$18.07 P/Share
|
|
Aug 11
2022
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
300
-0.2%
|
$6,000
$20.01 P/Share
|
|
Jul 11
2022
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
594
-0.49%
|
$10,098
$17.48 P/Share
|
|
Jul 01
2022
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,394
-0.43%
|
$25,092
$18.16 P/Share
|
|
May 19
2022
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+32.61%
|
-
|
|
May 19
2022
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+28.63%
|
-
|
|
May 19
2022
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+27.31%
|
-
|
|
May 19
2022
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+28.63%
|
-
|
|
May 19
2022
|
Neil F. Mc Farlane Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+30.57%
|
-
|
|
May 19
2022
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+19.44%
|
-
|
|
May 19
2022
|
Gwen A Melincoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+28.63%
|
-
|
|
May 19
2022
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+33.37%
|
-
|
|
Apr 06
2022
|
Neil F. Mc Farlane Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,845
+50.0%
|
-
|
|
Mar 16
2022
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-0.49%
|
$13,212
$18.99 P/Share
|
|
Mar 01
2022
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
76,094
-9.76%
|
$1,369,692
$18.71 P/Share
|
|
Feb 18
2022
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,559
-8.01%
|
$221,739
$21.61 P/Share
|
|
Feb 10
2022
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,659
-3.81%
|
$181,203
$17.63 P/Share
|
|
Feb 10
2022
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,175
+18.86%
|
-
|
|
Feb 10
2022
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
11,179
-3.55%
|
$190,043
$17.63 P/Share
|
|
Feb 10
2022
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
71,041
+18.1%
|
-
|
|
Feb 10
2022
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
52,997
-6.02%
|
$900,949
$17.63 P/Share
|
|
Feb 10
2022
|
Joseph Ciaffoni President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
190,034
+18.43%
|
-
|
|
Feb 10
2022
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,058
-2.23%
|
$68,986
$17.63 P/Share
|
|
Feb 10
2022
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,712
+19.3%
|
-
|
|
Feb 10
2022
|
Richard Malamut EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,300
-2.33%
|
$107,100
$17.63 P/Share
|
|
Feb 10
2022
|
Richard Malamut EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,006
+13.19%
|
-
|
|
Jan 10
2022
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-0.91%
|
$13,319
$19.05 P/Share
|
|
Jan 03
2022
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,090
-0.41%
|
$19,620
$18.68 P/Share
|
|
Dec 15
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,693
-6.89%
|
$102,474
$18.33 P/Share
|
|
Sep 16
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-0.82%
|
$13,946
$19.67 P/Share
|
|
Aug 10
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,386
-0.52%
|
$26,334
$19.03 P/Share
|
|
Aug 10
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,386
-0.96%
|
$26,334
$19.03 P/Share
|
|
Jul 12
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
595
-0.71%
|
$13,685
$23.17 P/Share
|
|
Jul 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,394
-0.52%
|
$32,062
$23.99 P/Share
|
|
Jun 02
2021
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
5,861
-2.14%
|
$128,942
$22.81 P/Share
|
|
Jun 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
16,205
-2.83%
|
$372,715
$23.13 P/Share
|
|
Jun 01
2021
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,205
+5.3%
|
$129,640
$8.22 P/Share
|
|
Jun 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,672
-1.68%
|
$102,784
$22.9 P/Share
|
|
May 24
2021
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+50.0%
|
-
|
|
May 20
2021
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+32.18%
|
-
|
|
May 20
2021
|
Gwen A Melincoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+32.18%
|
-
|
|
May 20
2021
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+18.38%
|
-
|
|
May 20
2021
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+41.54%
|
-
|
|
May 20
2021
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+29.89%
|
-
|
|
May 20
2021
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+39.91%
|
-
|
|
May 20
2021
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+32.18%
|
-
|
|
May 10
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,000
-7.22%
|
$154,000
$22.77 P/Share
|